FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a substance-delivering carrier for the substance delivery to a bone marrow cell producing an extracellular matrix containing retinoid as a delivering agent, wherein the substance is a therapeutic agent, which inhibits the beginning, progression and/or recurrence of myelofibrosis.
EFFECT: invention provides the effective inhibition of the beginning, progression and recurrence of myelofibrosis.
10 cl, 14 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR TREATING RENAL FIBROSIS | 2011 |
|
RU2711531C2 |
| MEANS FOR KIDNEY FIBROSIS TREATMENT | 2011 |
|
RU2635460C2 |
| COMPOSITION FOR RECOVERY OF NORMAL TISSUE FROM FIBROUS TISSUE | 2011 |
|
RU2650796C2 |
| MEANS FOR INTESTINAL FIBROSIS TREATMENT | 2012 |
|
RU2637372C2 |
| THERAPEUTIC AGENT APPLICABLE IN PULMONARY FIBROSIS | 2009 |
|
RU2547571C2 |
| THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | 2015 |
|
RU2678968C2 |
| LIPOSOMS WITH RETYNOID TO STRENGTHEN hsp47 EXPRESSION MODULATION | 2012 |
|
RU2628694C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS AGAINST MALIGNANT TUMORS WITH RNAi MOLECULES DIRECTED AGAINST Hsp47 | 2015 |
|
RU2756253C2 |
| COMPOUNDS FOR TARGETED DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | 2012 |
|
RU2769872C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
